Precise oncotropism is required for successful systemic administration of next-generation oncolytic measles viruses (MVs). We have previously established a system for efficient post-entry targeting by insertion of synthetic microRNA target sites (miRTS) into the MV genome, thereby repressing replication in the presence of cognate microRNAs. Thus, differential expression of microRNAs, as frequently observed in normal compared with malignant tissues, can be exploited to increase vector specificity and safety. Here we report the combination of miRTS for different microRNAs in a single vector to detarget pivotal organs at risk during systemic administration (liver, brain, gastrointestinal tract). Accordingly, miRTS for miR-122, miR-7 and miR-148a that are enriched in these tissues were inserted to create multi-tissue-detargeted MV (MV-EGFP mtd ). Replication of MV-EGFP mtd is repressed in cell lines as well as in non-transformed primary human hepatocytes and liver slices expressing cognate microRNAs. Oncolytic potency of MV-EGFP mtd is retained in a model of pancreatic cancer in vitro and in vivo. This work is a proof-of-concept that favorable expression profiles of multiple microRNAs can be exploited concomitantly to reshape the tropism of MV without compromising oncolytic efficacy. This strategy can be adapted to different vectors and cancer entities for safe and efficient high-dose systemic administration in clinical trials.
INTRODUCTION
Oncolytic viruses constitute a novel class of tumor-specific, selfreplicating anti-cancer therapeutics offering the promise of avoiding cross-resistance to conventional therapeutic modalities. The Edmonston B vaccine strain of measles virus (MV) is a candidate currently being investigated in preclinical and clinical settings of virotherapy. Results of the first clinical phase I trials are encouraging with early signs of efficacy, even though maximum tolerated doses have not been reached so far. 1, 2 The mechanism of tumor cell destruction is largely based on MV's lytic replication cycle and induction of apoptosis. 3 In addition, we and others have developed strategies to enhance the natural oncotropism as well as to optimize tumor cell killing, immune evasion and stimulation of an anti-tumor immune response. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Simultaneously, the maximum feasible dose of recombinant MV has been raised from 10 9 TCID 50 administered in the first 1 to 10 11 TCID 50 administered in the most recently reported clinical phase I trial. 2 However, clinical translation of more potent oncolytic vectors and systemic administration of increased viral doses may uncover severe adverse reactions limiting the therapeutic index. Ensuring safe applicability in heavily pretreated tumor patients with frequently impaired liver function should therefore be an integral component in the development of next-generation oncolytic viruses.
Currently, for the treatment of metastasized solid tumors systemic administration of therapy is standard of care. In this regard, intravenous delivery of oncolytic MV is the favored route of application, which on the one hand enables virus delivery to disseminated disease locations but on the other hand poses a potential safety risk due to exposure of healthy tissues to replicating viruses.
Precise restriction of viral tropism to tumor cells adds to the safety profile of oncolytic viruses by reducing off-target replication as a source of potential adverse reactions. To this end, we have previously adapted a post-entry targeting technique to MV based on the incorporation of microRNA target sites (miRTS) into the viral genome. 7 On condition of differential microRNA expression, this modification leads to repression of viral replication in healthy tissues expressing the cognate microRNA, while the absence of the same microRNA in transformed cells still permits efficient tumor cell killing. This targeting strategy has been shown to be compatible with a broad range of virus classes, including adenovirus, herpes simplex virus and vesicular stomatitis virus. [16] [17] [18] [19] [20] To further enhance vector specificity, insertion of a combination of miRTS for different microRNAs enriched in relevant non-target tissues is desirable. In this context, the liver is a pivotal organ exposed to all substances in the blood stream, and MV has been shown to be present in the liver after intravenous administration in MV-susceptible mice. 21 Moreover, impaired liver function often limits therapeutic options in pretreated tumor patients with advanced disease stages. It has been demonstrated that liverspecific miR-122 can provide liver-detargeting using miR-122 target sites in oncolytic viruses, including adenovirus and herpes simplex virus. [22] [23] [24] [25] [26] Another important organ to protect from off-target effects is the brain. We have previously shown that miR-7 enables detargeting of non-transformed brain tissue in MV-susceptible mice. 7 Additionally, miR-148a can be exploited for protection of gastrointestinal (GI) organs as it is enriched in normal pancreatic and several GI tract tissues. [27] [28] [29] Here, we report the generation and characterization of a triple microRNA-regulated, multi-tissue-detargeted oncolytic MV without compromised oncolytic efficacy.
MATERIALS AND METHODS

Cell culture
Vero cells (African green monkey kidney cells) and the pancreatic carcinoma (PC) cell line BxPC-3 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). PC cell lines MIA PaCa-2 and T3M4 were kindly provided by Zahari Raykov (DKFZ, Heidelberg, Germany). Hepatocellular carcinoma (HCC) cell lines Hep G2, PLC/PRF/5 and Huh-7 were kindly provided by Ulrich M. Lauer (University Hospital Tübingen, Tübingen, Germany). Isolated primary human hepatocytes (PHH; Ready Heps fresh hepatocytes, catalog no.: CC-2692A) were purchased from Lonza and cultured in hepatocyte culture medium (HCM; Lonza, Cologne, Germany). Vero cells and HCC cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Darmstadt, Germany) supplemented with 10% fetal bovine serum (DMEM+). PC cell lines were cultured in RPMI 1640 (Life Technologies) supplemented with 10% fetal bovine serum (RPMI+). All cells were cultured at 37°C in a humidified atmosphere of 5% CO 2 . All cell lines were confirmed to be free of mycoplasma contamination (VenorGeM Mycoplasma Detection Kit, Minerva Biolabs, Berlin, Germany).
Recombinant MVs
Custom-designed DNA oligonucleotides encoding the respective miRTSboxes (reference microRNA sequences according to http://www.mirbase. org) or reverse complementary control boxes (rc-boxes) flanked by overhanging ends for insertion into PacI (F gene 3′ untranslated region (UTR)) or SpeI (H gene 3′UTR) restriction sites were ordered (Eurofins, Ebersberg, Germany). Each miRTS-box contains three spacer-separated target sites which are 100% complementary to the cognate microRNA. Rc-boxes were designed by substituting the segments of miRTS-boxes encoding the actual miRTS with their reverse complementary sequences.
Expression plasmids pCG-F or -H encoding the MV-F or -H gene including their native 3′UTRs were linearized with restriction enzymes PacI or SpeI and were ligated with the respective oligonucleotides to create pCG-F_miRTS-148a and pCG-H_miRTS-122. To generate full-length MV genomic cDNA plasmids containing the miRTS-modified 3′UTRs, first, the NarI-PacI fragment of pMV-EGFP (derived from the Edmonston B vaccine lineage) was exchanged for the NarI-PacI fragment from pCG-F_miRTS-148a containing the miRTS-modified F 3′UTR to obtain pMV-EGFP-F_miRTS-148a. Second, the PacI-SpeI fragment of pMV-EGFP-F_miRTS-148a was exchanged for the PacI-SpeI fragment of pCG-H_miRTS-122 containing the miRTS-modified H 3′UTR to obtain pMV-EGFP-F_miRTS-148a-H_miRTS-122. Third, the miRTS-7 oligonucleotide was directly ligated into the SpeI linearized pMV-EGFP-F_miRTS-148a-H_miRTS-122 to obtain pMV-EGFP-F_miRTS-148a-H_miRTS-122_miRTS-7. The control virus genomic cDNA pMV-EGFP-F_miRTS-148arc-H_miRTS--122rc_miRTS-7rc was created analogously.
MiRTS-box and rc-box containing MV genomic plasmids, as well as the parental pMV-EGFP, were rescued in a modification of the procedure described by Radecke et al. 30 to generate MV-EGFP mtd , MV-EGFP rc and MV-EGFP. All viruses were propagated on Vero cells, and virus stocks from the second and third passage were used for experiments.
Virus titration
Virus titrations were carried out in octuplicates in 96-well plates. Virus suspensions were serially diluted 1:10 in 100 μl DMEM+ per well. Vero cells (45 000 cells cm ) were added to each well, and plates were incubated (37°C, 5% CO 2 ). Forty-eight hours postinfection (p.i.) syncytia were counted at an appropriate dilution step, and titers were calculated as cell infectious units (ciu) ml − 1 . To determine the titers of viral stocks, aliquots were thawed, vortexed briefly and directly used for titration. For the determination of viral progeny titers, samples were scraped, frozen in liquid nitrogen and stored at − 80°C. After thawing, samples were vortexed vigorously and centrifuged at 6 000 g for 5 min, and supernatants were used for titration.
Pre-microRNA transfection
Vero cells were plated in six-well plates at a density of 30 000 cells cm 
In vitro infection experiments
For assessment of viral spread and replication in the presence or absence of exogenous microRNAs, Vero cells were transfected with microRNA precursors (pre-miR-122, -7 and -148a) as described above or mock transfected (Opti-MEM+Lipofectamine 2000 only) in triplicates. Six hours post transfection, cells were infected at a multiplicity of infection (MOI) of 0.03 by removing the standard culture medium and adding the calculated amount of the respective viruses in Opti-MEM or Opti-MEM only (mock) to each well. Viruses were allowed to adsorb to the cells in an incubator (37°C, 5% CO 2 ) for 2 h before virus suspensions were removed, cells were washed, standard culture medium was added and plates were placed back into the incubator.
For assessment of viral spread and replication in the presence of endogenous microRNAs, PHH were infected at an MOI of 0.1 in triplicates as previously described. 31 Viruses were added to the cells in HCM (HCM only for mock infection). After adsorption overnight, virus suspensions were removed, cells were washed, fresh HCM was added and plates were incubated at 37°C. HCM was exchanged again after 24 h.
Infected cells were regularly observed for syncytia formation, and images were taken at 40 h p.i. were defined as 100 ciu ml − 1 .
Multi-step growth curves
Vero cells were plated in six-well plates at a density of 40 000 cm − 2 . Six hours later, cells were infected in triplicates at an MOI of 0.03 in Opti-MEM. BxPC-3 cells were plated in six-well plates at a density of 25 000 cm − 2 , allowed to attach overnight and infected in triplicates at an MOI of 0.3 in RPMI+. Viruses were allowed to adsorb for 2 h (Vero cells) or overnight (BxPC-3 cells) in an incubator (37°C, 5% CO 2 ), before virus suspensions were removed, cells were washed, culture media were added and plates were incubated at 37°C. At the designated time points (24, 36, 48 , 72 and 96 h), cells were scraped in their media, and viral progeny titers were determined as described above.
Cell viability assays MIA PaCa-2, T3M4, BxPC-3 and Vero cells were infected in standard culture media in quadruplicates at an MOI of 0.3 or mock infected and subsequently plated in 96-well plates at a density of 30 000 cm 
Immunoblots
Vero cells were transfected with microRNA precursors (pre-miR-122, -7 and -148a) and infected with MV-EGFP mtd or MV-EGFP rc as described above. Thirty-four hours p.i., cells were washed and lysed in 300 μl RIPA buffer (Fisher Scientific, Schwerte, Germany) supplemented with a protease inhibitor cocktail (cOmplete ULTRA Tablets; Roche, Mannheim, Germany). After 5 min of incubation, supernatants were collected and centrifuged at 3000 g (4°C) for 10 min. Supernatants were collected, and Roti-Load buffer (Carl Roth, Karlsruhe, Germany) was added. Samples were denatured at 95°C for 5 min and were subjected to SDS-PAGE in precast gels (10% Mini-PROTEAN TGX Precast Gel; Bio-Rad, Munich, Germany) and Tris/Glycin/SDS buffer at 200 V for 45 min. Proteins were blotted (wet, 100 V, 45 min) onto PVDF membranes (Immobilon P; Merck Millipore, Schwalbach, Germany) that were subsequently blocked in 5% dry milk in TBST (blocking buffer) at 4°C overnight. For immunodetection, membranes were incubated in blocking buffer with primary anti-MV-F, -H (kindly provided by Michael Mühlebach, Paul-Ehrlich Institute, Langen, Germany) and -N (kindly provided by Roberto Cattaneo, Mayo Clinic, Rochester, MN, USA) rabbit antibodies at concentrations of 1:3.500 (anti-F, anti-H) or 1:10.000 (anti-N) at room temperature for 90 min. Primary antibodies were removed, membranes were washed sufficiently in TBST and incubated in blocking buffer with an anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:10.000; Bethyl Laboratories, Montgomery, TX, USA) or an anti-β-actin-peroxidase antibody for 60 min. After sufficient washing, membranes were incubated in horseradish peroxidase substrate buffer (Super Signal West Dura Chemiluminescent Substrate; Fisher Scientific) for 2 min. Chemoluminiscence detection was performed in a ChemiDoc XRS+ Imaging System (Bio-Rad) using the Image Lab 3.0 software (Bio-Rad).
Primary human liver slices (PHLS)
Patient's informed consent was obtained according to the research proposals approved by the institutional review boards at Heidelberg Medical Faculty. Primary human liver tissue was provided by the surgical department of the Heidelberg University Hospital and was sectioned (300-μm thickness) on a vibratome (Leica VT1200 S; Leica Microsystems, Wetzlar, Germany) in supplemented Krebs-Henseleit buffer (4°C) immediately upon receipt as published previously. 32 PHLS were cultured using cell culture inserts for six-wells (3.0 μm; BD Biosciences, Heidelberg, Germany) in William's Medium E (Life Technologies) containing 434 mg l − 1 l-alanyl-lglutamine and supplemented with 25 mM glucose and 50 μg ml − 1 gentamicin at 37°C and 5% CO 2 . For infection, PHLS were incubated overnight in 2 ml of virus suspensions containing 1 × 10 7 ciu ml − 1 of MV-EGFP mtd , MV-EGFP rc or MV-EGFP in supplemented William's Medium E or were incubated in supplemented medium only (mock). Media were changed once daily, and imaging was performed 96 h p.i.
miR-122 quantification
Total RNA (including small RNAs) was isolated from cell lines or primary hepatocytes using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). MiR-122-5p molecules (used as standards during quantitative reverse transcription-PCR) were ordered as 5′-phosphorylated RNA oligos with the following sequence: 5′-P-UGGAGUGUGACAAUGGUGUUUG-3′ (Eurofins, Ebersberg, Germany). Standards were prepared by combining 300 ng E. Coli total RNA (Sigma-Aldrich, Munich, Germany) and defined numbers of miR-122-5p molecules (10 9 -10 2 in 1:10 serial dilutions). cDNAs of all samples and standards were synthesized using miScript II RT Kit (Qiagen). Quantitative PCR-based absolute quantification of microRNAs was performed using the miScript SYBR Green PCR Kit (Qiagen) and miScript Primer Assays (Qiagen) on a Light Cycler 480 (Roche). Crossing point values were calculated using the second-derivative maximum method; absolute numbers of miR-122-5p molecules per cell were calculated using the standard curve derived from the above-mentioned standards.
Statistical analyses
All data were analyzed using descriptive statistics. Calculations were performed in GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA); the significance level was set to α ⩽ 5%. P-values for comparison of viral progeny titers in microRNA-transfected Vero cells were calculated using an unpaired t-test with Welch's correction (for unequal variances). Comparison of survival curves from the in vivo experiment (murine xenograft model of PC) was done using the log-rank (Mantel-Cox) test, while average tumor volumes at day 52 from the same experiment were compared using an unpaired t-test with Welch's correction.
RESULTS
Genetic design of MV-EGFP mtd
A genomic map of MV-EGFP mtd carrying three 90 nt miRTS-boxes for three different microRNAs is depicted in Figure 1a . Each miRTSbox contains three spacer-separated copies of a sequence 100% complementary to the respective microRNA (Figure 1b) . As the nascent MV genomic RNA transcript is immediately encapsidated by the viral nucleocapsid (N) protein 33 and is therefore not accessible to microRNAs 7 , miRTS-boxes were designed to interact with microRNAs on the level of viral mRNA. A miRTS-box for microRNA-148a was inserted into the 3′UTR of the MV fusion (F) gene, whereas miRTS-boxes for microRNA-122 and microRNA-7 were inserted into the 3′UTR of the MV hemagglutinin (H) gene in tandem. A microRNA-insensitive control virus (MV-EGFP rc ) was created by inserting reverse complementary boxes (rc-boxes), analogously. On the mRNA level, these rc-boxes are sequenceidentical (that is, non-complementary) to the cognate microRNAs, and therefore a relevant base pairing between viral mRNAs and cellular microRNAs does not occur. MicroRNA-mediated silencing of gene expression ultimately leads to reduced protein levels regardless of the microRNA's mode of action on the targeted mRNA. 34 Reduced protein expression from targeted viral genes in the presence of cognate microRNAs was confirmed by immunoblotting of protein lysates from premicroRNA-or mock-transfected and subsequently infected Vero cells (Figure 2b) . A pronounced reduction in viral proteins in the presence of microRNAs was observed for MV-EGFP mtd but not for MV-EGFP rc . Furthermore, for MV-EGFP mtd , microRNAs decreased protein expression not only from miRTS-box-containing (H protein for miR-122/-7 and F protein for miR-148a) but also from unaltered viral genes (F protein for miR-122/-7; N protein for all microRNAs). This effect was stronger for miR-122 and -7 than for miR-148a.
Spread and replication of MV-EGFP
mtd are attenuated in the presence of exogenous cognate microRNAs The interaction of the F and H proteins and the host cell membrane mediates viral entry as well as fusion of infected cells with uninfected neighboring cells (syncytia formation). 35, 36 Downregulation of either one of these proteins by microRNA targeting should therefore result in reduced formation and spread of syncytia in tissue culture, as has been shown for downregulation of the F protein. 7 The degree of attenuation mediated by the inserted miRTS-boxes was assessed in Vero cells transfected with the cognate pre-microRNAs. In Figure 3a , viral spread of MV-EGFP mtd , MV-EGFP rc and MV-EGFP in the absence and in the presence of each individual microRNA is shown. Spread of all viruses in the absence of transfected pre-microRNAs as well as spread of MV-EGFP rc and MV-EGFP independently of premicroRNA transfection was comparable. In contrast, spread of MV mtd was reduced by 63, 56 and 33% in pre-miR-122, -miR-7, and -miR-148a transfected cells, respectively. Viral replication was assessed by titration of viral progeny production from premicroRNA-or mock-transfected and subsequently infected Vero cells and was found to correlate with viral spread (Figure 3b ). In the presence of miR-122, -7 and -148a, viral progeny titers of MV-EGFP rc were not significantly altered, whereas MV-EGFP mtd showed a reduction in progeny titers of 95-fold (P = 0.01), 12-fold (P = 0.02) and 5-fold (P = 0.03), respectively.
In vitro cytotoxicity of MV-EGFP mtd is retained in pancreatic carcinoma (PC) cell lines After having confirmed the functionality of all miRTS-boxes, oncolytic efficacy of MV-EGFP mtd was analyzed in vitro. A set of PC cell lines (BxPC-3, T3M4, MIA PaCa-2) was infected with MV-EGFP mtd , MV-EGFP rc and MV-EGFP at an MOI of 0.3. Cell viability was determined at 120 h p.i. and showed comparable reduction by all viruses, although with a tendency towards a slightly stronger effect of MV-EGFP rc and MV-EGFP (Figure 4a ). Sensitivity to MV oncolysis of the PC cell lines tested varied, which is consistent with previous observations. 5 Across all three viruses, 
MV-EGFP
mtd retains potent oncolytic efficacy in a murine xenograft model of pancreatic carcinoma The relevance of the slight reduction in cytotoxicity of MV-EGFP mtd in vitro was analyzed in vivo in a murine xenograft model of PC ( Figure 5 ). BxPC-3 cells were implanted subcutaneously into the right flank of 6-8-week-old, female NOD-SCID mice to form xenograft tumors. Treatment consisted of either intratumoral injection of MV-EGFP mtd or MV-EGFP or injection of carrier medium only (mock). Tumor volumes were measured, and mice were monitored for the occurrence of predefined termination criteria every 3 days. Both MV-EGFP mtd -and MV-EGFP-treated animals showed a pronounced delay in tumor progression resulting in prolongation of overall survival, although no sustained complete remissions were observed and all treated tumors progressed eventually. At day 52, when the first mock-treated animal had to be killed, the average tumor volume in this group was 709 μl compared with 88 μl in the MV-EGFP mtd -treated and 54 μl in the MV-EGFP-treated animals (Figures 5a and b) , with statistically significant differences between the virus-treated groups and the mock-treated group (P o 0.0001 for both comparisons). Median overall survival in the MV-EGFP mtd -and the MV-EGFP-treated groups was 96 and 98 days compared with 61 days in the mock-treated animals (Figure 5c ). Analysis of overall survival revealed significant differences (P o 0.0001) between mock and each of the treatment groups and no significant difference (P40.05) between the MV-EGFP and MV-EGFP mtd groups.
mtd is attenuated in isolated primary human hepatocytes (PHH) and primary human liver slices (PHLS) Isolated PHH and ex vivo cultured human PHLS are susceptible to MV infection 31, 32 and were therefore chosen as a model for the assessment of attenuation of MV-EGFP mtd in the presence of endogenous microRNA expressed at natural levels in a non-target tissue.
Endogenous miR-122 expression in PHH was quantified by reverse transcription followed by quantitative real-time PCR and found to be 51 115 molecules per hepatocyte. Abundant expression of microRNA-122 in human liver specimens is well documented. 22, 23 Therefore, healthy primary human liver tissue was obtained from a surgical specimen and immediately sectioned (300-μm thickness) to generate PHLS which were incubated in culture medium containing 2 × 10 
DISCUSSION
This work demonstrates that integration of several miRTS-boxes into a single MV vector can add to its safety profile by detargeting multiple tissues at risk without compromising oncolytic efficacy. Oncolytic virotherapy using recombinant MV has progressed into clinical trials for several cancer entities. Results of a clinical phase I trial for ovarian cancer have been published and clinical phase I trials for myeloma, glioblastoma, head and neck cancer and mesothelioma are ongoing. 1, 37 Limited by technical constraints in virus production at that time, a maximum dose of 10 9 TCID 50 was applied intraperitoneally in the published trial for ovarian cancer that dose-dependently resulted in a best objective response of stable disease. showed impressive responses in two selected patients intravenously treated at the current maximum feasible dose of 10
11
TCID 50 as part of the phase I trial for myeloma. Complete trial data have not been published yet. In both patients, bone marrow plasmacytosis resolved completely, and other relevant disease parameters were influenced beneficially, however, with differing extent and durability between both patients. Adverse effects included flu-like symptoms, hypotonia and tachycardia. Specific organ toxicities were not observed. In this study, anti-tumor efficacy seemed to be directly correlated with administered viral doses. As maximum tolerated dose was still not reached at 10 11 TCID 50 , future studies will aim for further dose escalation. Moreover, recombinant MVs expressing potent transgenes for enhanced tumor cell killing are currently in development 4 and are expected to provide not only additional benefit to cancer patients but also carry an increased risk of toxicity. Precise restriction of viral tropism to target tumor cells is therefore highly desirable to refute such toxicity concerns accompanying the consequent translation of these advancements to the clinic.
MicroRNA targeting is broadly applicable to many virus classes, and miRTS have proven to be largely uncritical to replication kinetics in the absence of cognate microRNAs due to their small size. MicroRNAs differentially expressed in normal and malignant tissues as well as microRNA expression profiles of major tissues of the body have been published and deposited in databases, which provide a source for disease context-specific microRNA selection. 29, 38, 39 Combinations of multiple miRTS as well as combinations with other targeting strategies can be implemented to tailor the natural tropism of oncolytic viruses to a specific cancer entity. Sugio et al.
40 generated a cancer-specific promoterdependent oncolytic adenovirus containing miRTS for miR-122 and miR-199a. Fu et al. 25 combined a liver-specific promoter and miRTS for miR-122, miR-124 and let-7 in an oncolytic herpes simplex virus.
In our combinatorial approach, we aimed at detargeting several tissues at risk during systemic administration of a virotherapeutic in patients with disseminated malignant disease. We chose miRTS for miR-122 (liver), miR-7 (brain, endocrine pancreas) and miR-148a (pancreas, GI organs), which are enriched in these important non-target tissues, and demonstrated that multiple miRTS-boxes can be inserted into the same MV vector for multitissue detargeting. Attenuation of MV-EGFP mtd by each of the cognate microRNAs was confirmed in the presence of exogenously transfected microRNAs, however, with differing efficiencies. Whereas miR-122 caused a reduction in viral progeny production of about two orders of magnitude, the effect size of miR-7 and miR-148a was lower. We have previously shown a reduction of viral progeny production by miR-7 of more than two orders of magnitude using the same miRTS but inserted within the F instead of the H 3′UTR. 7 The current position of the miRTS for miR-7 in the MV H 3′UTR downstream of the miRTS for miR-122 may cause weaker attenuation. These findings are in line with studies on vesicular stomatitis virus, another negative-stranded RNA virus, emphasizing the importance of miRTS positioning within the genome. 18 Thus, further investigation and establishment of additional insertion sites within the MV genome are needed to reveal the most favorable insertion pattern for multiple miRTS.
To address the comparatively low attenuation mediated by miR-148a, we investigated miR-375, another microRNA enriched in pancreatic and other GI tissues and downregulated in PC [27] [28] [29] but found it to be inferior to miR-148a (data not shown). For future studies of microRNA detargeting in the context of PC, other suitable microRNAs should therefore be evaluated to ensure efficient detargeting of these tissues at risk.
Finally, attenuation of MV-EGFP mtd in the presence of endogenously expressed miR-122 in human liver tissue was demonstrated. Primary human liver slices are widely used as an ex vivo model of the human liver and have previously been shown to express sufficient levels of miR-122 to attenuate replication of a miR-122-detargeted adenovirus. 26 The observed reduction in the spread of MV-EGFP mtd in the PHLS was confirmed in isolated primary human hepatocytes, where progeny virus production by MV-EGFP mtd was shown to be markedly reduced. Proof of principle for miR-122-mediated attenuation of MV in primary human liver tissue provides a detargeting strategy for the development of tumor-specific oncolytic MV for HCC treatment, as miR-122 is frequently downregulated in HCC cell lines as wells as in primary human HCC samples. 22, 41 In summary, we have shown that favorable expression profiles of multiple microRNAs can be exploited concomitantly to reshape the tropism of MV without compromising oncolytic efficacy. This targeting approach can be adapted to enhance safety in future systemic high-dose administration of next-generation MV vectors with increased potency.
